

The information in the press release is intended for investors.

Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 3, 2023

Today on May 3, 2023 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its annual general meeting (“AGM”) at which the following principal resolutions were passed.

Adoption of income statements and balance sheets for 2022 and discharge from liability

The AGM resolved to adopt the income statements and balance sheets for the company and the group for the financial year 2022. The members of the board of directors and the CEO were discharged from liability for the financial year 2022.

Allocation of earnings

The AGM resolved that no dividend shall be paid for 2022 and that the company's unappropriated earnings shall be carried forward.

Election of board members and auditors, and fees to the board of directors and auditors

The AGM resolved that the number of members of the board of directors shall be four without deputies and that the number of auditors shall be one registered accounting firm.

The AGM re-elected Mats Franzén, Jan-Eric Österlund and Jonas Pedersén and elected Annika Freij as member of the board of directors. Mats Franzén was re-elected as chairman of the board of directors.

The registered accounting firm KPMG AB was re-elected as auditor of the company and it was noted that the authorised accountant Daniel Haglund will be auditor-in-charge.

The AGM resolved that fees to the chairman of the board of directors shall be paid with SEK 550,000, to each of the other members of the board of directors with SEK 250,000, to the chairman of the audit committee with SEK 125,000, to each of the other members of the audit committee with SEK 75,000, to the chairman of the remuneration committee with SEK 75,000 and to each of the other members of the remuneration committee with SEK 50,000.

The AGM resolved that members of the board of directors (in addition to remuneration for expenses relating to travel and accommodation) domiciled in Europe, but outside the Nordic countries, shall receive a remuneration of SEK 7,500 per physical board meeting.

The AGM resolved that remuneration, for services rendered by the auditor of the company, shall be paid in accordance with approved invoice.

Approval of the board of directors' remuneration report

The AGM resolved to approve the remuneration report for the financial year 2022.

For more information, please contact

Isofol Medical AB (publ)

Mats Franzén, chairman of the board

E-post: mats@efficere.se

Thomas Andersson, CEO

E-mail: thomas.andersson@isofolmedical.com

Phone: +46 (0)709-44 00 93

The information was submitted for publication, through the agency of the contact person set out above, at 18:40 CEST on May 3, 2023.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com